Enhertu Hits Primary Endpoint in First-Line HER2-Mutant Lung Cancer

summarizeSummary

Enhertu demonstrated a statistically significant improvement in progression-free survival versus standard of care in first-line HER2-mutant NSCLC, marking a first for this patient population.

check_boxKey Events · Product Development and Regulatory · AZN

• Primary Endpoint Met

  Enhertu showed statistically significant and clinically meaningful improvement in progression-free survival versus platinum-pemetrexed chemotherapy plus pembrolizumab in the DESTINY-Lung04 Phase III trial for first-line HER2-mutant NSCLC.

• First-in-Class Achievement

  Enhertu is the first and only HER2-directed medicine to improve PFS over global standard of care in a Phase III trial in the first-line setting for HER2-mutant NSCLC.

• Trial Design and Enrollment

  DESTINY-Lung04 enrolled 454 patients across Asia, Europe, and North America, randomized 1:1 to Enhertu or standard of care, with PFS by blinded independent central review as the primary endpoint.

• Safety Profile Consistent

  The safety profile of Enhertu was generally consistent with its known profile, with no new safety concerns identified.

auto_awesomeAnalysis · AZN · Life Sciences

AstraZeneca and Daiichi Sankyo's Enhertu met its primary endpoint of progression-free survival in the DESTINY-Lung04 Phase III trial, becoming the first HER2-directed therapy to show a PFS benefit over standard of care in the first-line setting for HER2-mutant NSCLC. This expands Enhertu's addressable market into a larger, earlier-line patient population and strengthens AstraZeneca's oncology franchise. The positive data supports potential regulatory submissions and label expansion, which could drive significant future revenue growth.